Efficacy of tadalafil in men with erectile dysfunction naïve to phosphodiesterase 5 inhibitor therapy compared with prior responders to sildenafil citrate

Journal of Sexual Medicine

Volumn 3, Issue 4, 2006, Pages 668-675

  Broderick, Gregory A ^a   Donatucci, Craig F ^b   Hatzichristou, Dimitrios ^c   Torres, Luiz O ^d   Valiquette, Luc ^e   Zhao, Yanli ^f   Loughney, Kate ^f   Sides, Gregory D ^f   Ahuja, Sanjeev ^f  

^a MAYO CLINIC   (United States)

^b DUKE UNIVERSITY   (United States)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d Clinica de Urologia e Andrologia   (Brazil)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^f ELI LILLY AND COMPANY   (United States)

Author keywords

Erectile dysfunction; Sildenafil; Tadalafil; Treatment na ve

Indexed keywords

PLACEBO; SILDENAFIL; TADALAFIL;

ANALYSIS OF COVARIANCE; ARTICLE; BACKACHE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG EFFICACY; DRUG EXPOSURE; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPEPSIA; ERECTILE DYSFUNCTION; GEOGRAPHIC DISTRIBUTION; HUMAN; LOGISTIC REGRESSION ANALYSIS; META ANALYSIS; PARALLEL DESIGN; PENIS ERECTION; POST HOC ANALYSIS; PRIORITY JOURNAL; RHINOPHARYNGITIS; SCORING SYSTEM; SEXUAL INTERCOURSE; SEXUAL SATISFACTION; STATISTICAL MODEL; TIME SERIES ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 33745230777     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2006.00273.x     Document Type: Article

References (17)

1. Lue TF, Giuliano F, Montorsi F, Rosen RC, Andersson KE, Althof S, Christ G, Hatzichristou D, Hirsch M, Kimoto Y, Lewis R, McKenna K, MacMahon C, Morales A, Mulcahy J, Padma-Nathan H, Pryor J, de Tejada IS, Shabsigh R, Wagner G. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2004; 1: 6-23.
2. Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins VS, Anglin G, Whitaker JS. Efficacy and safety of tadalafil in the treatment of erectile dysfunction: Results of integrated analyses. J Urol 2002; 168: 1332-6.
3. Carson CC, Rajfer J, Eardley I, Carrier S, Denne JS, Walker DJ, Shen W, Cordell WH. The efficacy and safety of tadalafil: An update. BJU Int 2004; 93: 1276-81.
4. Lewis RW, Sadovsky R, Eardley I, O'Leary M, Seftel A, Wang WC, Shen W, Walker DJ, Wong DG, Ahuja S. The efficacy of tadalafil in clinical populations. J Sex Med 2005; 2: 517-31.
5. Fonseca V, Seftel A, Denne J, Fredlund P. Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: Analysis of data from tadalafil clinical trials. Diabetologia 2004; 47: 1914-23.
6. Montorsi F, Nathan HP, McCullough A, Brock GB, Broderick G, Ahuja S, Whitaker S, Hoover A, Novack D, Murphy A, Varanese L. Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: A randomized, double-blind, placebo controlled trial. J Urol 2004; 172: 1036-41. Erratum in: J Urol 2005;173:664.
7. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The International Index of Erectile Function (IIEF): A multidimensional scale for the assessment of erectile dysfunction. Urology 1997; 49: 822-30.
8. Jarow JP, Burnett AL, Geringer AM. Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment. J Urol 1999; 162: 722-5.
9. Martinez-Jabaloyas JM, Gil-Salom M, Villamon-Fort R, Pastor-Hernandez F, Martinez-Garcia R, Garcia-Sisamon F. Prognostic factors for response to sildenafil in patients with erectile dysfunction. Eur Urol 2001; 40: 641-6.
10. Atiemo HO, Szostak MJ, Sklar GN. Salvage of sildenafil failures referred from primary care physicians. J Urol 2003; 170: 2356-8.
11. Gonzalgo ML, Brotzman M, Trock BJ, Geringer AM, Burnett AL, Jarow JP. Clinical efficacy of sildenafil citrate and predictors of long-term response. J Urol 2003; 170: 503-6.
12. Shabsigh R. Hypogonadism and erectile dysfunction: The role for testosterone therapy. Int J Impot Res 2003; 15(suppl 4): S9-13.
13. Hatzichristou D, Moysidis K, Apostolidis A, Bekos A, Tzortzis V, Hatzimouratidis K, Ioannidis E. Sildenafil failures may be due to inadequate patient instructions and follow-up: A study on 100 non-responders. Eur Urol 2005; 47: 518-23.
14. Wespes E, Rammal A, Garbar C. Sildenafil non-responders: Haemodynamic and morphometric studies. Eur Urol 2005; 48: 136-9.
15. Jiann B-P, Yu C-C, Su C-C, Huang J-K. Rechallenge prior sildenafil nonresponders. Int J Impot Res 2004; 16: 64-8.
16. Forgue ST, Patterson BE, Bedding AW, Payne CD, Phillips DL, Wrishko RE, Mitchell MI. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2005; 61: 280-8.
17. Cialis® (tadalafil) United States Product Insert (USPI) (updated 7/8/ 05).